About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Ignorance Was Bliss | Main | The Universe, Which Others Call the Library. . . »

March 14, 2004

Mismatched Socks

Email This Entry

Posted by Derek

Some miscellaneous updates tonight, in addition to the note appended to the post below. It seems that Sunday nights don't often leave with time for more extensive blogging, and the world events of the last few days have made their claim on my attention as well. This isn't going to be one of those dull years, not that I expected it to be. In fact, I'm not sure when we're going to have one of those again.

Some readers (rather few) may be wondering what's been up with my long-running series of odd experiments, last seen crashing to earth in a rain of feathers and melting wax. I haven't set anything up in the lab since that, but I've been busy working on a presentation to go public (inside my company, anyway) with my ideas. The project, if it's going to work at all, is too big for me to do in the scientific equivalent of my garage. I'm going to make my case for some formal support, and it'll be interesting to see how that's received.

On another front, I wanted to mention that I closed out my short position in Imclone at about $45/share, a nice round loss from the $40 where I went short. I'm keeping an eye on the stock, and if it continues to rise (up into, say, the 60s with no change in the underlying situation), then I'll consider shorting it again. For now, though, discretion was the better part of a capital-gains loss. I continue to think that many IMCL investors suffer from an excess of optimism, but that's one of the engines of the market, isn't it? (I did make up that loss and more by shorting MSO, Martha Stewart's company, though. Write and I'll bore you with the details.)

And the Sanofi/Aventis dance continues, with Novartis hovering over the whole proceedings. This is yet another situation where those who say, don't know - because those who know aren't saying. Most of the public statements are designed to be, well, merely public statements, so their information value is questionable. It's going to be a while before we know how this one comes out, so I haven't been (and won't be) covering every twist and turn. If anything dramatic happens, I'll weigh in.

Comments (0) | Category: Birth of an Idea | Business and Markets



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry